Trade Resources Company News GSK Has Entered Into a Drug Discovery Alliance with Yale

GSK Has Entered Into a Drug Discovery Alliance with Yale

GlaxoSmithKline (GSK) has entered into a drug discovery alliance with Yale to design a potential new class of medicines that degrade disease-causing proteins.

Under the collaboration, GSK integrates its expertise in medicinal chemistry with Yale's work on proteolysis targeting chimeric molecules (PROTACs).

The PROTAC technology directs disease-causing proteins to a cell's garbage disposal where they can be destroyed.

Yale will be eligible for milestone and royalty payments for each protein-degrading drug that is discovered and developed, as per the agreement.

GSK Protein Degradation effort head Kris Famm said, "This partnership is exploring a new way for promising, but unproven therapeutic approaches to jump from the academic lab more quickly into the early stage pharmaceutical pipeline.

Source: http://drugdiscovery.pharmaceutical-business-review.com/news/gsk-yale-university-enter-into-drug-discovery-alliance-020512
Contribute Copyright Policy
Gsk, Yale University Enter Into Drug Discovery Alliance